Pheast Therapeutics, Inc.

Venture-backed company · Stage unknown· Redwood City, CApheast.com
Rounds on record
2
Latest round
Oct 7, 2025
Form D equity offering
Latest round size
$24.6M
Form D industry: Other Technology
More
Ask DFX about thisView relationshipsFinancing historyInvestorsOwnership and outcomes
As of · the latest observation of this company; each round carries its own date

1 additional officer or director, 3 additional investors

Every relationship, signal and contact on this record, with the source on each.

Includes 3 days of DFX Intelligence. Then $199/month unless canceled.

What matters now

  1. $24.6M
    sold on Form D

    Filed a Form D on 7 Oct 2025: $24.6M sold on Form D. A Form D is an offering filing; it names no investors, stage or valuation.

    A company that just raised has fresh capital, a new board and new vendors to choose.

    FactSEC Form DFor Investors, lenders, service providersFinancing history →
  2. 2 investors
    named

    2 investors on record.

    The investors already on the cap table shape who leads the next round.

    Factfunding announcements, portfolio pages and Form DFor Investors, foundersInvestors →
  3. 4 directors
    board

    4 directors on record from Form D filings and board-seat attributions.

    The board is who decides on the next round and on a sale.

    FactSEC Form D related personsFor Investors, acquirersPeople →
Drawing the relationship network…

Facts

Year of incorporation
2020sec.gov
Revenue range (Form D)
Decline to Disclosesec.gov
Rounds on record
2
Disclosed raised
unknownsum of rounds with a disclosed amount only
Named investors
2

Financing history

2 rounds
  1. Oct 7, 2025
    Form D equity offering · $24.6M (form d sold) · 7 investors
    Arch Venture Partners via Steven Nmn GillisCatalio Capital Management, LP via R. Jacob Vogelstein
    Fact Form D · “Pheast Therapeutics, Inc. filed Form D: $24,588,083 sold of $39,999,993, Other Technology”
  2. Jan 31, 2022
    Form D equity offering · $75.3M (form d sold) · 7 investors
    Arch Venture Partners via Steven Nmn GillisCatalio Capital Management, LP via R. Jacob Vogelstein
    Fact Form D · “Pheast Therapeutics, Inc. filed Form D/A: $75,250,000 sold of $75,250,000, Other Technology”

Investors on record

6 edges

Ownership and outcomes

none on record
Outcome stated by investors

Listed on 2 firm portfolio pages; none states an outcome (acquired, public, exited or active). DFX does not assume the company is active.

Evidence: 2 listingseach firm's own card, as read
No later owner or exit on record: no private equity sponsor position and no acquisition, listing or IPO report names this company.

Credit relationships

none on record
No lender position matched to this company.

People

3 officers, 4 directors
Show all 6 officers and directors

Timeline

2 events
  1. Oct 16, 2025
    Pheast Therapeutics, Inc. filed Form D: $24,588,083 sold of $39,999,993, Other Technology
    Form D filed Fact Form D
  2. Apr 10, 2025
    Pheast Therapeutics, Inc. filed Form D/A: $75,250,000 sold of $75,250,000, Other Technology
    Form D filed Fact Form D

Evidence

36 observations
Every observation on this company
  • Entity type: Corporation Oct 16, 2025 Fact Form D
  • Entity type: Corporation Apr 10, 2025 Fact Form D
  • Form D industry group: Other Technology Oct 16, 2025 Fact Form D
  • Form D industry group: Other Technology Apr 10, 2025 Fact Form D
  • Amendment: false Oct 16, 2025 Fact Form D
  • Amendment: true Apr 10, 2025 Fact Form D
  • Revenue range (Form D): Decline to Disclose Oct 16, 2025 Fact Form D
  • Revenue range (Form D): Decline to Disclose Apr 10, 2025 Fact Form D
  • Incorporated: withinFiveYears Oct 16, 2025 Fact Form D
  • Incorporated: withinFiveYears Apr 10, 2025 Fact Form D
  • Jurisdiction: Delaware Oct 16, 2025 Fact Form D
  • Jurisdiction: Delaware Apr 10, 2025 Fact Form D
  • Amount sold (Form D): $24.6M Oct 16, 2025 Fact Form D
  • Amount sold (Form D): $75.3M Apr 10, 2025 Fact Form D
  • Offering amount (Form D): $40.0M Oct 16, 2025 Fact Form D
  • Offering amount (Form D): $75.3M Apr 10, 2025 Fact Form D
  • Exemptions: 06b Oct 16, 2025 Fact Form D
  • Exemptions: 06b Apr 10, 2025 Fact Form D
  • First sale: 2025-10-07 Oct 16, 2025 Fact Form D
  • First sale: 2022-01-31 Apr 10, 2025 Fact Form D
  • Investors (Form D): 7 Oct 16, 2025 Fact Form D
  • Investors (Form D): 7 Apr 10, 2025 Fact Form D
  • Minimum investment (Form D): 0 Oct 16, 2025 Fact Form D
  • Minimum investment (Form D): 0 Apr 10, 2025 Fact Form D
  • Securities offered: Equity, option Oct 16, 2025 Fact Form D
  • Securities offered: equity Apr 10, 2025 Fact Form D
  • Office address: Oct 16, 2025 Fact Form D
  • Office address: Apr 10, 2025 Fact Form D
  • Listed on portfolio page: Sep 30, 2026 Fact
  • Listed on portfolio page: Sep 30, 2026 Fact
  • Listed on portfolio page: Sep 16, 2026 Fact
  • Listed on portfolio page: Sep 16, 2026 Fact
  • Listed on portfolio page: Sep 15, 2026 Fact
  • Listed on portfolio page: Sep 14, 2026 Fact
  • Year of incorporation: 2020 Oct 16, 2025 Fact Form D
  • Year of incorporation: 2020 Apr 10, 2025 Fact Form D

Relationships across DFX

on 1 other DFX graph
Across the graphs

Pheast Therapeutics, Inc. is the same institution as 1 record in Private Equity.

Private Equity1

The joined record opens with the product, beside every other relationship on this page.

Checking your plan…

Record history

2 dated events on the change ledger, latest event first
  • Form D filed
    2025-10-16source on record
  • Form D filed
    2025-04-10source on record

The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.